vorinostat has been researched along with Gastrointestinal Stromal Neoplasm in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mühlenberg, T | 1 |
| Zhang, Y | 1 |
| Wagner, AJ | 1 |
| Grabellus, F | 1 |
| Bradner, J | 1 |
| Taeger, G | 1 |
| Lang, H | 1 |
| Taguchi, T | 1 |
| Schuler, M | 1 |
| Fletcher, JA | 1 |
| Bauer, S | 1 |
1 other study available for vorinostat and Gastrointestinal Stromal Neoplasm
| Article | Year |
|---|---|
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
Topics: Acetylation; Apoptosis; Cell Line, Tumor; Enzyme Inhibitors; Gastrointestinal Stromal Tumors; Histon | 2009 |